The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy

by Yuki Shinno, MD, Yasushi Goto, MD, PhD, Mayu Ohuchi, Akinobu Hamada, Hiroshi Nokihara, Yasuhiro Fujiwara, Yuichiro Ohe
Published 2020-03-01